Showing results (11-20 of 306) with videos related to
Sort By:
Pageof 31
Chemmedchem|February 23, 2012
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathwayAnne Pick, Michael WieseFuture Medicinal Chemistry|August 22, 2015
Design of inhibitors of BCRP/ABCG2Kapil Juvale, Michael WieseJournal of Medicinal Chemistry|October 31, 2003
Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivityRomy Fleischer, Michael WieseJournal of Medicinal Chemistry|December 13, 2002
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis)Ilza K Pajeva, Michael WieseMedicinal Research Reviews|May 30, 2018
Small-molecule inhibitors of multidrug resistance-associated protein 1 and related processes: A historic approach and recent advancesSven Marcel Stefan, Michael WieseThe AAPS Journal|June 9, 2009
Structure-activity relationships of tariquidar analogs as multidrug resistance modulatorsIlza K Pajeva, Michael WieseExpert Opinion on Therapeutic Patents|April 29, 2014
HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616)Michael Wiese, Ilza K PajevaJournal of Medicinal Chemistry|April 10, 2015
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)Sebastian C Köhler, Michael WieseMedicinal Research Reviews|April 4, 2019
The A-B-C of small-molecule ABC transport protein modulators: From inhibition to activation-a case study of multidrug resistance-associated protein 1 (ABCC1)Michael Wiese, Sven Marcel StefanJournal of Medicinal Chemistry|May 6, 2016
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2)Michael K Krapf, Michael WiesePageof 31